The management of patients with major/life-threatening bleeding related to the use of direct-acting oral anticoagulants does not stop with reversal of the anticoagulant. Learn from the perspective of a neurocritical care pharmacy specialist about considerations in providing comprehensive care and continued assessment to patients after these bleeding events.
SPEAKERS
James S. Kalus, Pharm.D, FASHP, is Director of Pharmacy at Henry Ford Health System in Detroit, Michigan. He also is Program Director for the PGY1 residency at Henry Ford Hospital and adjunct assistant professor of pharmacy and medicine at Wayne State University. Dr. Kalus earned his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at the University of Toledo in Toledo, Ohio, and completed a residency and two-year cardiovascular research fellowship. His research has focused on cardiovascular disease, and he serves on the editorial board of Annals of Pharmacotherapy, Cardiology Panel. He recently completed an appointment to the ASHP Commission on Credentialing.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
Jason R. Vilar, Pharm.D., BCCCP, is Neurocritical Care Pharmacy Specialist and Co-Clinical Coordinator for the PGY1 pharmacy residency program at AdventHealth Orlando in Orlando, Florida. He also holds an assistant clinical professor position at the University of Florida College of Pharmacy. Dr. Vilar earned his Doctor of Pharmacy degree at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora, then completed a PGY1 pharmacy residency at Henry Ford Health System in Detroit and PGY2 critical care pharmacy residency at Wesley Medical Center in Wichita, Kansas. He is an active member of Neurocritical Care Society, Society of Critical Care Medicine, and ASHP.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
All others in control of the content of this activity do not have a relevant financial relationship (RFR) with an ineligible company.
This podcast is provided by ASHP and supported by an educational grant from Alexion Pharmaceuticals, Inc.
